The following announcement is from the national DBSA office. If you are interested in providing feedback on a clinical trial design for treating Major Depressive Disorder with esketamine, follow the “sign up here” link in DBSA’s announcement. This post is purely informational – please use your own judgment in deciding whether to participate.
Have you experienced Major Depressive Disorder (MDD) or have a loved one who has? Have you ever wondered what goes into designing clinical trials for medications? Would you like to use your experience to give feedback to clinical trial designers?
DBSA has an opportunity to provide feedback a clinical trial design for esketamine.
Putting wellness within every individual’s reach is at the core of DBSA’s mission, strategies, and programs. One key to that mission is educating researchers who design clinical trials.
Don’t miss out on this rare opportunity to share your perspective with a clinical trial designer.
If you’re interested in participating in this opportunity, sign up here.
DBSA looks forward to continued engagement with stakeholders and encourages comments to refine understanding of the clinical effectiveness and value of treatment.
Sharing your experiences will help put wellness within reach for many people living with MDD by spreading understanding of the impact and management of these life-threatening conditions.